Lisata Therapeutics talks ADC breakthrough with Catalent
Lisata Therapeutics Inc earlier this week discussed the potential of certepetide in antibody-drug conjugate (ADC) applications through a new collaboration...…
1,690$
4,32%
Echtzeit-Aktienkurs Pliant Therapeutics
Bid:
Ask:
Nachrichten zur Pliant Therapeutics Aktie
Lisata Therapeutics signs research license with Catalent
Lisata Therapeutics Inc (NASDAQ:LSTA) announced that it has entered into a research license agreement with Catalent to evaluate certepetide, its…
Lisata Therapeutics announces research license with Catalent
Lisata Therapeutics Inc (NASDAQ:LSTA) announced that it has entered into a research license agreement with Catalent to evaluate certepetide, its…
Original-Research: Lisata Therapeutics Inc (von First Berlin Equity Research ...
^Original-Research: Lisata Therapeutics Inc - from First Berlin EquityResearch GmbH01.04.2025 / 15:31 CET/CESTDissemination of a Research, transmitted by EQS News…
Lisata Therapeutics CEO discusses AI drug discovery collaboration
Lisata Therapeutics Inc (NASDAQ:LSTA) CEO David Mazzo joined Proactive to discuss the company’s strategic collaboration with GATC Health, a leader…
Lisata Therapeutics partners with GATC Health to advance AI-driven drug development
Lisata Therapeutics Inc (NASDAQ:LSTA) has announced the first step of an intended multi-part strategic agreement with GATC Health, a leading…
Pliant Therapeutics shares rise on better-than-expected Q4 earnings By Investing.com
Pliant Therapeutics shares rise on better-than-expected Q4 earnings…
Pliant Therapeutics Provides Update on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis
SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that…
Lisata Therapeutics CEO: 2025 to be ‘data-rich’ as certepetide trials progress
Lisata Therapeutics Inc (NASDAQ:LSTA) CEO David Mazza told investors that he expects 2025 to be a “data-rich year” in a…
Original-Research: Lisata Therapeutics Inc (von First Berlin Equity Research ...
^Original-Research: Lisata Therapeutics Inc - from First Berlin EquityResearch GmbH29.01.2025 / 09:50 CET/CESTDissemination of a Research, transmitted by EQS News…
Lisata Therapeutics CEO discusses recent pancreatic cancer trial milestones
Lisata Therapeutics Inc (NASDAQ:LSTA) joined Proactive to discuss the latest updates from the compays pancreatic cancer trials. The company recently...…
Lisata Therapeutics and WARPNINE unveil positive preliminary results from pancreatic cancer trial
Lisata Therapeutics Inc (NASDAQ:LSTA) and WARPNINE have announced promising preliminary results from their Phase 1b/2a iLSTA trial, which is evaluating...…
Lisata Therapeutics unveils encouraging preliminary data from Phase 2 pancreatic cancer trial
Lisata Therapeutics Inc (NASDAQ:LSTA) has reported encouraging preliminary data for Cohort A of its ongoing ASCEND Phase 2 trial. The…
Original-Research: Lisata Therapeutics Inc (von First Berlin Equity Research ...
^Original-Research: Lisata Therapeutics Inc - from First Berlin EquityResearch GmbH21.01.2025 / 13:55 CET/CESTDissemination of a Research, transmitted by EQS News…
Lisata Therapeutics advances certepetide with trial enrollment milestone and new diagnostic partnership
Lisata Therapeutics Inc (NASDAQ:LSTA) shares were reacting positively this week after the company announced further developments for its lead...…
Lisata Therapeutics completes patient enrollment for CENDIFOX trial
Lisata Therapeutics Inc (NASDAQ:LSTA) announced that it has completed patient enrollment in all three cohorts of its Phase 1b/2a CENDIFOX…
Lisata Therapeutics completes patient enrollment for solid tumor cancer trial
Lisata Therapeutics Inc (NASDAQ:LSTA) announced that it has completed patient enrollment in all three cohorts of its Phase 1b/2a CENDIFOX…
Lisata Therapeutics and Kuva Labs to collaborate on cancer imaging solution
Lisata Therapeutics Inc (NASDAQ:LSTA) has announced a collaboration and license agreement with Kuva Labs, a wholly owned subsidiary of Mi2…
Lisata Therapeutics named ‘Specialized BioTherapeutics Company of the Year’ at 2024 BioTech Breakthrough Awards
Lisata Therapeutics Inc (NASDAQ:LSTA) has been awarded the title of ‘Specialized BioTherapeutics Company of the Year’ at the 2024 BioTech…
Lisata Therapeutics wins BioTech Breakthrough award
Lisata Therapeutics Inc (NASDAQ:LSTA) has been awarded the title of ‘Specialized BioTherapeutics Company of the Year’ at the 2024 BioTech…
Lisata Therapeutics CEO discusses pancreatic cancer trial progress and new collaborations
Lisata Therapeutics Inc (NASDAQ:LSTA) CEO David Mazzo joined Proactive to talk about the latest updates on its clinical trials and…
Lisata Therapeutics advances clinical trials in Q3 ahead of data-rich 2025
Lisata Therapeutics Inc (NASDAQ:LSTA) reported significant advancements across its clinical portfolio in the third quarter, with multiple key data readouts...…
Lisata Therapeutics forms partnership for preclinical cancer immunotherapy study
Lisata Therapeutics Inc (NASDAQ:LSTA), the US-based clinical-stage pharmaceutical company, announced a preclinical research collaboration to explore a novel...…
Lisata Therapeutics and Valo Therapeutics partner in preclinical study on cancer immunotherapy
Lisata Therapeutics Inc (NASDAQ:LSTA), the US-based clinical-stage pharmaceutical company, and Finnish immunotherapy developer Valo Therapeutics Oy have...…
Lisata Therapeutics partners with University of Cincinnati to investigate endometriosis therapy
Lisata Therapeutics Inc (NASDAQ:LSTA) chief medical officer Dr Kristen Buck discussed with Proactive a promising collaboration between the company and…
Lisata Therapeutics strikes research partnership to investigate new treatment for endometriosis
Lisata Therapeutics Inc (NASDAQ:LSTA) has entered a research agreement with the University of Cincinnati to study the use of its cyclic…
Pliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), today announced that…
Lisata Therapeutics begins treating second cohort of patients in bile duct cancer trial
Lisata Therapeutics Inc (NASDAQ:LSTA) announced that it has started treatment of the first patient in the second-line cholangiocarcinoma (CCA) cohort…
Lisata Therapeutics’ certepetide receives Orphan Drug Designation for cholangiocarcinoma
Lisata Therapeutics Inc (NASDAQ:LSTA) announced today that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation to…
Pliant Therapeutics Announces Four Upcoming Presentations at the European Respiratory Society International Congress 2024
SOUTH SAN FRANCISCO, Calif., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a late-stage biotechnology…
Lisata Therapeutics coming off strong 2Q performance, CEO says
Lisata Therapeutics Inc (NASDAQ:LSTA) CEO David Mazzo told shareholders that the company is coming off a quarter with “strong momentum”…
Lisata Therapeutics CMO details pancreatic cancer research collaboration with Haystack Oncology
Lisata Therapeutics Inc (NASDAQ:LSTA) chief medical officer Kristen Buck joined Proactive to discuss the company’s new research collaboration with Haystack...…
Lisata Therapeutics partners with Haystack Oncology to advance pancreatic cancer therapy research
Lisata Therapeutics Inc (NASDAQ:LSTA) has announced a research collaboration with Haystack Oncology using Haystack’s MRD technology to evaluate the efficacy...…
Lisata Therapeutics completes enrollment in Phase 2a BOLSTER trial for certepetide in bile duct cancer
Lisata Therapeutics Inc (NASDAQ:LSTA) said it has completed enrollment in its Phase 2a BOLSTER trial for certepetide, a promising investigational…
Lisata’s certepetide showing promising early results as cholangiocarcinoma treatment
Lisata Therapeutics Inc (NASDAQ:LSTA) chief medical officer Kristen Buck talked with Proactive about encouraging preclinical results for their drug...…
Pliant Therapeutics CBO sells shares worth over $114k By Investing.com
Pliant Therapeutics CBO sells shares worth over $114k…
Lisata Therapeutics shares promising pre-clinical data
Lisata Therapeutics Inc (NASDAQ:LSTA) has unveiled encouraging preclinical results for its drug candidate, certepetide, in intrahepatic cholangiocarcinoma,...…
Lisata Therapeutics CEO discusses enrollment milestone for pancreatic cancer trial
Lisata Therapeutics Inc (NASDAQ:LSTA) CEO David Mazzo joined Proactive to discuss a recent milestone for the company: the completion of…
Lisata Therapeutics completes pancreatic cancer cohort enrollment in CENDIFOX trial
Lisata Therapeutics Inc (NASDAQ:LSTA) announced it has completed enrollment in the pancreatic cancer cohort of its Phase 1b/2a CENDIFOX trial.…
Pliant Therapeutics Presents Data from its Bexotegrast Program at the European Association for the Study of the Liver (EASL) International Liver Congress™
SOUTH SAN FRANCISCO, Calif., June 06, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a late-stage biotechnology…
How does Lisata Therapeutics have a negative enterprise value?
Lisata Therapeutics Inc (NASDAQ:LSTA) finds itself in an extraordinary but not unusual position emblematic of the challenges faced by small-cap biotech...…
Pliant Therapeutics Presents Data from its Bexotegrast Program at the American Thoracic Society International Conference
SOUTH SAN FRANCISCO, Calif., May 21, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology…
Lisata Therapeutics receives waiver for pediatric studies of certepetide in pancreatic cancer
Lisata Therapeutics Inc (NASDAQ:LSTA) has received a Paediatric Investigation Plan (PIP) waiver from the European Medicines Agency (EMA) for its…
Lisata Therapeutics reports strong 1Q performance, cash to support operations into 2026
Lisata Therapeutics Inc (NASDAQ:LSTA) has ended its first quarter of 2024 with nearly $43.3 million in cash to fund its…